Crohn's News Blog

Weblog – Informação sobre DII

Archive for the ‘Crohn’s disease’ Category

Primeiro acampamento para jovens com doença inflamatória do intestino

with one comment

DII | Doença inflamatória do intestino afecta 15 mil pessoas

A 2 e 3 de Julho vai realizar-se o primeiro acampamento para jovens com doença inflamatória do intestino

Nos próximos dias 2 e 3 de Julho, a Associação Portuguesa da Doença Inflamatória do Intestino (APDI), com o apoio do GEDII (Grupo de Estudos da Doença Inflamatória Intestinal) e da Abbott, vai promover o primeiro acampamento para jovens portadores desta doença, que afecta 15 mil pessoas, no Parque de Campismo de Montargil, no Alentejo, avança comunicado de imprensa.

Esta iniciativa, que conta já com a participação de mais de 80 jovens com idades entre os 18 e 25 anos, tem como objectivo proporcionar um momento de interacção e troca de experiências entre os participantes e procurar assim contribuir para que estes doentes consigam lidar melhor com o estigma social a que estão muitas vezes sujeitos.
Leia o resto deste artigo »

Written by CarlAn

01/07/2011 at 12:53

GSK moves Crohn’s disease drug into phase III

leave a comment »

Crohn’s disease

GlaxoSmithKline and its partner ChemoCentryx have started late-stage trials of GSK’786 for Crohn’s disease.

The initial study is a randomised, double-blind, placebo-controlled study that will involve approximately 600 patients to evaluate 500mg of ‘786 once-daily or twice-daily compared to placebo in patients with moderately-to-severely active Crohn’s disease.

The primary and key secondary endpoints are the proportion of subjects achieving a treatment-induced clinical response based on the Crohn’s Disease Activity Index (CDAI) and the proportion of subjects achieving clinical remission.
Leia o resto deste artigo »

Written by CarlAn

18/01/2011 at 18:46

What’s behind Humira’s bullish forecast?

with 2 comments

What’s behind Humira’s bullish forecast?

A report predicting that Humira will become the world’s biggest product in two years’ time generated positive news for the Abbott Labs/Eisai arthritis drug. Several factors are driving the bullish forecast.

While growth is by no means a given, analysts are actually optimistic about the entire class of biologics called TNF inhibitors, which are often used to treat rheumatic diseases, like rheumatoid arthritis (RA), ankylosing spondylitis, Crohn’s disease, psoriasis and ulcerative colitis. According to the forecast, by EvaluatePharma, Humira will become the top-selling anti-TNF—and the world’s biggest product—in 2012 with global sales of $8.3 billion and will retain its top spot until 2016, when sales could exceed $10 billion. Anti-TNF drugs from Pfizer/Amgen (Enbrel) and Johnson & Johnson/Merck (Remicade) will reach the no. 3 and no. 7 spots on the top-10 list, the forecast noted.

Jeffrey Stewart, who heads up Abbott’s US Humira business, summed up the reasons why analysts are keen on these drugs. “The unmet need is great, the therapeutic gain and net value is very significant vs. the standard of care, and a significant number of patients [for whom anti-TNF drugs are indicated] still have not been put on these medications,” said Stewart, who is divisional VP for immunology, in Abbott’s pharmaceutical products division.

Read More…»»What’s behind Humira’s bullish forecast?


Powered by ScribeFire.

Written by CarlAn

06/05/2010 at 17:09

New Studies Presented at Digestive Disease Week Highlight the Value of PillCam(R) Capsule Endoscopy

with 2 comments

More Than 68 PillCam(R) SB and PillCam(R) ESO Studies Presented; Company to Host Conference Call on May 7 at 1:00pm ET to Review DDW Abstract Highlights

Given Imaging Ltd. today announced that new studies confirmed the value of using PillCam(R) SB more frequently and earlier in the diagnostic algorithm in a range of disease states, including anemia, confirmed or clinically suspected Crohn’s disease, upper gastrointestinal bleeding and occult or obscure gastrointestinal bleeding (OGIB).

The studies concluded that PillCam SB is able to accelerate the time to diagnosing these conditions and often can obviate the need for additional diagnostic tests. Additional studies showed the value of PillCam(R) ESO as an emergency room tool to expedite triaging of patients presenting with upper gastrointestinal bleeding (UGIB) or non-cardiac chest pain. More than 68 studies were presented on PIllCam SB and PillCam ESO at the Digestive Disease Week(R) (DDW) 2010 conference concluding today in New Orleans.

NEW ORLEANS, LA, May 05, 2010 (COMTEX)
Given Imaging Ltd. /quotes/comstock/15*!givn/quotes/nls/givn (GIVN
20.10, -0.75, -3.60%)

Read More…

, ,

Powered by ScribeFire.

Written by CarlAn

06/05/2010 at 00:08

Meebo Chat Room

with one comment

%d bloggers like this: